Who makes Statin Recapture Therapy?

Statin Recapture Therapy is developed by University of Cologne.

What development phase is Statin Recapture Therapy in?

Statin Recapture Therapy is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Statin Recapture Therapy

University of Cologne · FDA-approved active Small molecule Quality 2/100

Statin Recapture Therapy, developed by the University of Cologne, is a marketed drug with a key composition patent expiring in 2028. The primary strength of this therapy lies in its unique mechanism, which differentiates it from existing treatments. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	Statin Recapture Therapy
Also known as	Simvastatin 80 mg, Atorvastatin 80 mg, Pravastatin 40 mg, Fluvastatin 80 mg
Sponsor	University of Cologne
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Statin Recapture Therapy Before Coronary Artery Bypass Grafting (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Statin Recapture Therapy CI brief — competitive landscape report
Statin Recapture Therapy updates RSS · CI watch RSS
University of Cologne portfolio CI